Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

The primary objective of this study is to characterize the safety profile of sotorasib.

Inclusion Criteria:

• Adult (≥ 18 years) as of the index date.
• KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
• Received at least 1 dose of sotorasib.
• Receipt of at least 1 prior systemic therapy before use of sotorasib.
• Obtained ICF, if required.

Exclusion Criteria:

• Documentation of being a non-Chinese ethnicity.